Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Pulmonary Emphysema HELP
Based on 2,670 articles published since 2008
||||

These are the 2670 published articles about Pulmonary Emphysema that originated from Worldwide during 2008-2019.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
1 Guideline Endobronchial Coils for Endoscopic Lung Volume Reduction: Best Practice Recommendations from an Expert Panel. 2018

Slebos, Dirk-Jan / Ten Hacken, Nick H / Hetzel, Martin / Herth, Felix J F / Shah, Pallav L. ·Department of Pulmonary Diseases, University of Groningen, University Medical Center Groningen (UMCG), Groningen, the Netherlands. · Groningen Research Institute for Asthma and COPD, University of Groningen, University Medical Center Groningen (UMCG), Groningen, the Netherlands. · Krankenhaus vom Roten Kreuz, Stuttgart, Germany. · Thoraxklinik and Translational Lung Research Center (TLRC), University of Heidelberg, Heidelberg, Germany. · Royal Brompton and Harefield NHS Foundation Trust, London, United Kingdom. · Chelsea and Westminster Hospital NHS Foundation Trust, London, United Kingdom. · National Heart and Lung Institute, Imperial College, London, United Kingdom. ·Respiration · Pubmed #29991060.

ABSTRACT: Endobronchial coils are an additional treatment option for lung volume reduction in patients with severe emphysema. Patient selection should be focused on patients with severe emphysema on optimal medical therapy and with evidence of severe hyperinflation. The technique is suitable in a broad range of patients with emphysema; however, patients with paraseptal emphysema, large focal (giant) bullae, significant co-morbidity and airway-predominant disease should be avoided. Treatment involves placing between 10 and 14 coils by bronchoscopy in the selected treatment lobe, with 2 lobes being treated sequentially. Lobe selection for treatment should be based on quantitative computed tomography, and the lobes with the greatest destruction should be targeted (excluding the right middle lobe). The treatment results in an improvement in pulmonary function, exercise performance and quality of life, particularly in patients with severe hyperinflation (residual volume > 200% predicted) and upper-lobe heterogeneous emphysema, but will also be of benefit in lower-lobe predominant and homogeneous emphysema. Finally, it has an acceptable safety profile, although special attention has to be paid to coil-associated opacity which is an inflammatory response that occurs in some patients treated with endobronchial coils.

2 Guideline Spanish Guidelines for Management of Chronic Obstructive Pulmonary Disease (GesEPOC) 2017. Pharmacological Treatment of Stable Phase. 2017

Miravitlles, Marc / Soler-Cataluña, Juan José / Calle, Myriam / Molina, Jesús / Almagro, Pere / Quintano, José Antonio / Trigueros, Juan Antonio / Cosío, Borja G / Casanova, Ciro / Antonio Riesco, Juan / Simonet, Pere / Rigau, David / Soriano, Joan B / Ancochea, Julio. ·Servicio de Neumología, Hospital Universitari Vall d'Hebron, Barcelona, España; CIBER de Enfermedades Respiratorias (CIBERES), España. Electronic address: mmiravitlles@vhebron.net. · Servicio de Neumología, Hospital Arnau de Vilanova-Lliria, Valencia, España. · Servicio de Neumología, Hospital Clínico San Carlos, Departamento de Medicina, Facultad de Medicina, Universidad Complutense de Madrid, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, España. · Centro de Salud Francia, Dirección Asistencial Oeste, Madrid, España. · Servicio de Medicina Interna, Hospital Universitario Mutua de Terrassa, Terrassa, España. · Centro de Salud Lucena I, Lucena, Córdoba, España. · Centro de Salud Menasalbas, Toledo, España. · Hospital Universitario Son Espases-IdISBa, Palma de Mallorca, España; CIBER de Enfermedades Respiratorias (CIBERES), España. · Servicio de Neumología-Unidad de Investigación, Hospital Universitario La Candelaria, Tenerife, España. · Servicio de Neumología, Hospital San Pedro de Alcántara, Cáceres, España. · Centro de Salud Viladecans-2, Dirección Atención Primaria Costa de Ponent-Institut Català de la Salut, Institut Universitari d'Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol), Barcelona, España. · Centro Cochrane Iberoamericano, Barcelona, España. · Instituto de Investigación Hospital Universitario de La Princesa (IISP), Universidad Autónoma de Madrid, Consultor Metodológico y de Investigación de SEPAR, Madrid, España. · Servicio de Neumología, Hospital Universitario de La Princesa, Instituto de Investigación, Hospital Universitario de La Princesa (IISP), Universidad Autónoma de Madrid, Madrid, España. ·Arch Bronconeumol · Pubmed #28477954.

ABSTRACT: The clinical presentation of chronic obstructive pulmonary disease (COPD) varies widely, so treatment must be tailored according to the level of risk and phenotype. In 2012, the Spanish COPD Guidelines (GesEPOC) first established pharmacological treatment regimens based on clinical phenotypes. These regimens were subsequently adopted by other national guidelines, and since then, have been backed up by new evidence. In this 2017 update, the original severity classification has been replaced by a much simpler risk classification (low or high risk), on the basis of lung function, dyspnea grade, and history of exacerbations, while determination of clinical phenotype is recommended only in high-risk patients. The same clinical phenotypes have been maintained: non-exacerbator, asthma-COPD overlap (ACO), exacerbator with emphysema, and exacerbator with bronchitis. Pharmacological treatment of COPD is based on bronchodilators, the only treatment recommended in low-risk patients. High-risk patients will receive different drugs in addition to bronchodilators, depending on their clinical phenotype. GesEPOC reflects a more individualized approach to COPD treatment, according to patient clinical characteristics and level of risk or complexity.

3 Guideline Guidelines for the medical treatment of idiopathic pulmonary fibrosis. 2017

Xaubet, Antoni / Molina-Molina, María / Acosta, Orlando / Bollo, Elena / Castillo, Diego / Fernández-Fabrellas, Estrella / Rodríguez-Portal, José Antonio / Valenzuela, Claudia / Ancochea, Julio. ·Servicio de Neumología, Hospital Clínic, Barcelona, España; Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), España. Electronic address: axaubetmir@gmail.com. · Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), España; Unidad Funcional del Intersticio Pulmonar (UFIP), Servicio de Neumología, Hospital Universitario de Bellvitge-Instituto de Investigación Biomédica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Barcelona, España. · Servicio de Neumología, Hospital Universitario de Canarias, Santa Cruz de Tenerife, España. · Servicio de Neumología, Complejo Asistencial Universitario de León, León, España. · Servicio de Neumología, Hospital de la Santa Creu i Sant Pau, Barcelona, España. · Servicio de Neumología, Consorcio Hospital General Universitario de Valencia, Valencia, España. · Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), España; Servicio de Neumología, Hospital Universitario Virgen del Rocío, Sevilla, España. · Servicio de Neumología, Hospital Universitario de La Princesa, Universidad Autónoma de Madrid, Madrid, España. ·Arch Bronconeumol · Pubmed #28292522.

ABSTRACT: Idiopathic pulmonary fibrosis is defined as chronic fibrosing interstitial pneumonia limited to the lung, with poor prognosis. The incidence has been rising in recent years probably due to improved diagnostic methods and increased life expectancy. In 2013, the SEPAR guidelines for the diagnosis and treatment for idiopathic pulmonary fibrosis were published. Since then, clinical trials and meta-analyses have shown strong scientific evidence for the use of pirfenidone and nintedanib in the treatment of idiopathic pulmonary fibrosis. In 2015, the international consensus of 2011 was updated and new therapeutic recommendations were established, prompting us to update our recommendation for the medical treatment of idiopathic pulmonary fibrosis accordingly. Diagnostic aspects and non-pharmacological treatment will not be discussed as no relevant developments have emerged since the 2013 guidelines.

4 Guideline Guidelines for the diagnosis and treatment of idiopathic pulmonary fibrosis. Sociedad Española de Neumología y Cirugía Torácica (SEPAR) Research Group on Diffuse Pulmonary Diseases. 2013

Xaubet, Antoni / Ancochea, Julio / Bollo, Elena / Fernández-Fabrellas, Estrella / Franquet, Tomás / Molina-Molina, Maria / Montero, Maria Angeles / Serrano-Mollar, Anna / Anonymous2960760. ·Servicio de Neumología, Hospital Clínic, Barcelona, España. axaubet@clinic.ub.es ·Arch Bronconeumol · Pubmed #23742884.

ABSTRACT: Idiopathic pulmonary fibrosis is defined as a chronic fibrosing interstitial pneumonia limited to the lung, of unknown cause, with poor prognosis and few treatment options. In recent years there has been an increase in their prevalence, probably due to the optimization of diagnostic methods and increased life expectancy. The ATS/ERS Consensus (2000) established the diagnostic criteria and recommendations for the assessment of the disease course and treatment. Later studies have helped to redefine diagnostic criteria and treatment options. In 2011, an international consensus was published, establishing diagnostic criteria and new treatment strategies. These guidelines have been updated with the newest aspects of diagnosis and treatment of idiopathic pulmonary fibrosis. A level of evidence has been identified for the most relevant questions, particularly with regard to treatment options.

5 Guideline Spanish COPD Guidelines (GesEPOC): pharmacological treatment of stable COPD. Spanish Society of Pulmonology and Thoracic Surgery. 2012

Miravitlles, Marc / Soler-Cataluña, Juan José / Calle, Myriam / Molina, Jesús / Almagro, Pere / Quintano, José Antonio / Riesco, Juan Antonio / Trigueros, Juan Antonio / Piñera, Pascual / Simón, Adolfo / López-Campos, José Luis / Soriano, Joan B / Ancochea, Julio / Anonymous2520725. ·Institut d'Investigacions Biomèdiques August Pi i Sunyer, Hospital Clínic, Barcelona, España. marcm@separ.es ·Arch Bronconeumol · Pubmed #22561012.

ABSTRACT: Recognizing the clinical heterogeneity of COPD suggests a specific therapeutic approach directed by the so-called clinical phenotypes of the disease. The Spanish COPD Guidelines (GesEPOC) is an initiative of SEPAR, which, together with the scientific societies involved in COPD patient care, and the Spanish Patient Forum, has developed these new clinical practice guidelines. This present article describes the severity classification and the pharmacological treatment of stable COPD. GesEPOC identifies four clinical phenotypes with differential treatment: non-exacerbator, mixed COPD-asthma, exacerbator with emphysema and exacerbator with chronic bronchitis. Pharmacological treatment of COPD is based on bronchodilation in addition to other drugs depending on the clinical phenotype and severity. Severity is established by the BODE/BODEx multidimensional scales. Severity can also be approximated by assessing airflow obstruction, dyspnea, level of physical activity and history of exacerbations. GesEPOC is a new, more individualized approach to COPD treatment according to the clinical characteristics of the patients.

6 Editorial Cellular Senescence in Chronic Obstructive Pulmonary Disease: Multifaceted and Multifunctional. 2018

Antony, Veena B / Thannickal, Victor J. ·1 Department of Medicine University of Alabama at Birmingham Birmingham, Alabama. ·Am J Respir Cell Mol Biol · Pubmed #30067090.

ABSTRACT: -- No abstract --

7 Editorial Pulmonary hypertension in combined pulmonary fibrosis and emphysema: A tale of two cities. 2018

Goh, Nicole S L. ·Department of Respiratory and Sleep Medicine, Austin Health, Melbourne, VIC, Australia. ·Respirology · Pubmed #29527780.

ABSTRACT: -- No abstract --

8 Editorial On Don Quixote and pink puffers: multi-organ loss of tissue COPD. 2018

Soriano, Joan B / Burgel, Pierre-Régis. ·Instituto de Investigación, Hospital Universitario de la Princesa (IISP) Universidad Autónoma de Madrid, Madrid, Spain jbsoriano2@gmail.com. · Sociedad Española de Neumología y Cirugía Torácica, Barcelona, Spain. · University Paris Descartes (EA2511), Paris, France. · Dept of Respiratory Medicine, Cochin Hospital, AP-HP, Paris, France. ·Eur Respir J · Pubmed #29437949.

ABSTRACT: -- No abstract --

9 Editorial Endobronchial valve placement in emphysema: When is it lung volume reduction? 2018

Eberhardt, Ralf. ·Department of Pneumology and Critical Care Medicine, Thoraxklinik, University of Heidelberg, Heidelberg, Germany. · Translational Lung Research Center Heidelberg (TLRCH), German Center for Lung Research (DZL), Heidelberg, Germany. ·Respirology · Pubmed #29105909.

ABSTRACT: -- No abstract --

10 Editorial Integrative Genomics of Emphysema-Associated Genes: Are We Closer to Identifying the Genetic Determinants of Lung Function? 2017

Sharma, Sunita. ·1 Division of Pulmonary Sciences and Critical Care Medicine University of Colorado Denver, Colorado. ·Am J Respir Cell Mol Biol · Pubmed #28960108.

ABSTRACT: -- No abstract --

11 Editorial More Options for Treating Severe Hyperinflation in Advanced Emphysema. 2017

Criner, Gerard. ·1 Temple University School of Medicine Philadelphia, Pennsylvania. ·Am J Respir Crit Care Med · Pubmed #28926283.

ABSTRACT: -- No abstract --

12 Editorial Vulnerability and Genetic Susceptibility to Cigarette Smoke-Induced Emphysema in Mice. 2017

Rahman, Irfan / De Cunto, Giovanna / Sundar, Isaac K / Lungarella, Giuseppe. ·1 Department of Environmental Medicine University of Rochester Medical Center Rochester, New York and. · 2 Department of Molecular and Developmental Medicine University of Siena Siena, Italy. ·Am J Respir Cell Mol Biol · Pubmed #28862508.

ABSTRACT: -- No abstract --

13 Editorial A "GLI-tch" in Alveolar Myofibroblast Differentiation. 2017

Ahlfeld, Shawn K / Perl, Anne Karina. ·1 Divisions of Neonatology and Pulmonary Biology. · 2 Cincinnati Children's Hospital Medical Center Cincinnati, Ohio. ·Am J Respir Cell Mol Biol · Pubmed #28862507.

ABSTRACT: -- No abstract --

14 Editorial Combined pulmonary fibrosis and emphysema: bad and ugly all the same? 2017

Cottin, Vincent. ·Hospices civils de Lyon, Groupe Hospitalier Est, Service de pneumologie - centre de référence des maladies pulmonaires rares, Université de Lyon, Université Claude Bernard Lyon I, Lyon, France vincent.cottin@chu-lyon.fr. ·Eur Respir J · Pubmed #28679618.

ABSTRACT: -- No abstract --

15 Editorial A murine model of elastase- and cigarette smoke-induced emphysema: is it an opportunity to understand CT emphysema in humans? 2017

Santana, Alfredo Nicodemos Cruz. ·. Unidade Torácica, Hospital Regional da Asa Norte - HRAN - Escola Superior de Ciências da Saúde/Secretaria de Estado da Saúde - ESCS/SES - Brasília (DF) Brasil. ·J Bras Pneumol · Pubmed #28538771.

ABSTRACT: -- No abstract --

16 Editorial Controversies in Fibrosis and Emphysema. 2017

Antoniou, Katerina M / Bibaki, Eleni / Margaritopoulos, George A. ·Department of Thoracic Medicine, Faculty of Medicine, University of Crete, Heraklion, Greece. Electronic address: kantoniou@med.uoc.gr. · Department of Thoracic Medicine, Faculty of Medicine, University of Crete, Heraklion, Greece. · Interstitial Lung Disease Unit, Royal Brompton Hospital, London, UK. ·Arch Bronconeumol · Pubmed #28343743.

ABSTRACT: -- No abstract --

17 Editorial Lung Mass as the Complement to Lung Air Content in Quantitative CT of the COPD Lung. 2017

Hoffman, Eric A / Newell, John D. ·Department of Radiology, University of Iowa, 200 Hawkins Drive, Iowa City, IA 52240; Department of Biomedical Engineering, University of Iowa, Iowa City, Iowa. ·Acad Radiol · Pubmed #28262202.

ABSTRACT: -- No abstract --

18 Editorial Collateral Ventilation: Friend or Foe in Patients with Severe Emphysema. 2017

Slebos, Dirk-Jan / Shah, Pallav L. ·Department of Pulmonary Diseases, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. ·Respiration · Pubmed #28122373.

ABSTRACT: -- No abstract --

19 Editorial Precision medicine in COPD: Are we making it too difficult? 2017

de Jong, Pim A / Mohamed Hoesein, Firdaus. ·Department of Radiology and Nuclear Medicine, Division of Imaging, University Medical Center Utrecht, The Netherlands. ·Respirology · Pubmed #28102973.

ABSTRACT: -- No abstract --

20 Editorial Bullectomy: A Waste of Space or Room for Improvement? 2016

Kemp, Samuel V / Herth, Felix J F / Shah, Pallav L. ·The National Institute for Health Research Unit, Royal Brompton and Harefield NHS Foundation Trust, and Imperial College, London, UK. ·Respiration · Pubmed #27606836.

ABSTRACT: -- No abstract --

21 Editorial Idiopathic Pulmonary Fibrosis and Emphysema: Between Scylla and Charybdis. 2016

Tzilas, Vasilios / Tzouvelekis, Argyris / Papiris, Spyridon / Bouros, Demosthenes. ·1st Respiratory Medicine Department, Hospital for Diseases of the Chest 'Sotiria', Athens, Greece. ·Respiration · Pubmed #27603927.

ABSTRACT: -- No abstract --

22 Editorial Endoscopic valve therapy for emphysema: Patient selection as the Holy Grail to success. 2016

Valipour, Arschang. ·Department of Respiratory and Critical Care Medicine, Ludwig-Boltzmann-Institute for COPD and Respiratory Epidemiology, Vienna, Austria. ·Respirology · Pubmed #27549373.

ABSTRACT: -- No abstract --

23 Editorial Computed tomography-derived pathological phenotypes in COPD. 2016

MacNee, William. ·University of Edinburgh/MRC Centre for Inflammation Research, Queen's Medical Research Institute, Edinburgh, UK w.macnee@ed.ac.uk. ·Eur Respir J · Pubmed #27365503.

ABSTRACT: -- No abstract --

24 Editorial CT-diagnosed emphysema and lung cancer mortality: novel association or old news? 2016

Quint, Jennifer K. · ·Thorax · Pubmed #27103348.

ABSTRACT: -- No abstract --

25 Editorial Interventional Pulmonology: Marching Forward Together. 2016

Wahidi, Momen M. ·President of the American Association of Bronchology and Interventional Pulmonology. ·J Bronchology Interv Pulmonol · Pubmed #27058708.

ABSTRACT: -- No abstract --

Next